Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Helius Medical Technologies, Inc. - Class A Common Stock (NQ:HSDT)

4.590 UNCHANGED
Streaming Delayed Price Updated: 3:50 PM EDT, May 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Helius Medical Technologies, Inc. - Class A Common Stock

< Previous 1 2 3 Next >
Helius Medical Technologies, Inc. Announces Partnership with Lovell® Government Services to Expand Reach of PoNS Therapy™
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Helius Medical Technologies, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Helius Medical Technologies, Inc. to Release Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Helius Medical Technologies, Inc. Initiates Open-Label Study for Registrational Program in Stroke
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Helius Medical Technologies Inc. (NASDAQ: HSDT) Near the Top of Equities by Percentage Gain on 9/5
Via Investor Brand Network
Helius Medical Technologies, Inc. to Present at the 36th Annual ROTH Conference
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Helius Medical Technologies, Inc. Secures HCPCS Codes for Portable Neuromodulation Stimulator (PoNS®) Mouthpiece and Controller
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Helius Medical Technologies Inc. (NASDAQ: HSDT) is One of Tuesday Morning’s Most Active Stocks
Via Investor Brand Network
Helius Medical Technologies, Inc. Announces Alignment with FDA on Registrational Program for Treatment of Stroke Patients
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Helius Booth and Special Event at APTA Combined Sections Meeting Will Highlight Physical Therapists’ Ability to Customize PoNS Therapy® to Improve Gait in People with MS
Event Appearance Caps Year of Growth: PoNS®-Trained PTs Now Found Across the United States 
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Helius Medical Technologies, Inc. Announces Further Expansion of Stroke Clinical Program with the Addition of Brooks Rehabilitation Hospital
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Helius Medical Technologies to Present at NobleCon19 Annual Conference
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Helius Medical Technologies, Inc. Reports Third Quarter 2023 Financial Results
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Helius Medical Technologies, Inc. Announces Study Results Demonstrating That PoNS Therapy™ Helps Patients with Traumatic Brain Injury Return to Work
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Helius Medical Technologies, Inc. to Release Third Quarter 2023 Financial Results on November 9, 2023; Announces Extended Cash Runway into Q2 2024
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Helius Medical Technologies, Inc. Receives Letter of Intent from the Québec Ministry of Health and Social Services to Purchase 30 PoNS® Devices
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Helius Medical Technologies to Participate at Two Upcoming Healthcare Conferences
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Helius Medical Technologies, Inc. Receives UPC Numbers for its PoNS® System and Mouthpiece
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Helius to Bring its Innovative PoNS Therapy for Improvement of Gait in People with MS, to the 2023 Academy of Neurologic Physical Therapy Conference
From Helius Medical Technologies, Inc.
Via GlobeNewswire
University of Montreal’s School of Rehabilitation to Purchase Ten PoNS® Devices for Research Study on Stroke Recovery
-- The study will evaluate the optimal time to use PoNS Therapy™ during a patient’s stroke recovery journey -- 
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Helius Medical Technologies to Present at the 2023 Interdisciplinary Association of Functional Neuroscience and Rehabilitation Conference
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Helius Medical Technologies, Inc. Compliant with All Applicable Nasdaq Listing Criteria
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Helius Medical Technologies Announces Reverse Stock Split
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Helius Medical Technologies, Inc. Reports Second Quarter 2023 Financial Results
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Helius Medical Technologies, Inc. Announces Participation of Montefiore Medical Center in its PoNS® Therapeutic Experience Program
Sixth Center of Excellence added in multi-center, company-sponsored, open label observational interventional trial to evaluate the impact of subjects’ adherence to PoNS Therapy™ for gait improvement in... 
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Helius Medical Technologies, Inc. to Release Second Quarter 2023 Financial Results on August 10, 2023
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Helius Medical Technologies, Inc. Expands Stroke Trial at the Medical University of South Carolina
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Helius Medical Technologies Announces DMEPOS Accreditation for PoNS
-- Critical initial step toward US reimbursement -- 
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Helius Medical Technologies to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Helius to Highlight Innovative PoNS Therapy™ at the 2023 Consortium of Multiple Sclerosis Centers Annual Meeting, in Commemoration of World MS Day
From Helius Medical Technologies, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.